^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-21447

    i
    Other names: BGB-21447
    Associations

    News

    Trials
    Company:
    BeiGene
    Drug class:
    Bcl2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=85, Recruiting, BeiGene
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447
    10ms
    Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=66, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447
    1year
    Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, BeiGene
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC translocation
    |
    BGB-21447